Gain insights from Arvinas' Q1 2025 earnings call. Explore VEPDEG's regulatory milestones, restructuring plans, and financial strategy for long-term growth.

Arvinas, along with its partner Pfizer, cancelled plans for a Phase 3 trial combining its PROTAC vepdegestrant with its CDK4 ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

Pfizer is facing some revenue pressures due to some higher Medicare discounts. Read more to see why I upgrade PFE stock from ...

Despite breast cancer being the most common among Japanese women, the risk of developing noncancer diseases among female breast cancer survivors has not been explored in detail. Therefore, researchers ...

Pfizer stock jumped Tuesday after the S&P 500 drugmaker beat first-quarter profit expectations on the back of savvy cost-cutting measures.

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

Pfizer Inc. reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance. “Our overall solid first-quarter performance demonstrates our continued focus on ...

A three-year comprehensive project meant to help improve early detection, timely diagnosis and treatment of breast cancer in the country has ...

A genetic signature including four genes in gastric cancer is linked to an increase in recurrence and mortality.